title: Differential effects of growth hormone and alpha calcidol on trabecular and cortical bones in hypophysectomized rats.
abstract: Growth hormone (GH) deficiency in children causes severe growth retardation, vitamin D deficiency, and osteopenia. We investigated whether alfacalcidol (1OHD) alone or in combination with GH can improve bone formation. Forty hypophysectomized female rats (HX) at the age of 8 wk were divided into HX, HX + 1OHD (oral 0.25 microg/kg daily), HX+GH (0.666 mg/0.2 mL SC daily) and HX+GH + 1OHD groups for a 4-wk study. Results showed that GH increased body weight, bone area, bone mineral content (BMC), and bone mineral density (BMD), whereas 1OHD only increased BMC and BMD. In cortical bone, GH increased both periosteal and endocortical bone formation resulting in a significant increase in cortical size and area in percentage, whereas 1OHD suppressed endocortical erosion surface per bone surface (ES/BS) without a significant effect on bone formation rate per bone surface (BFR/BS). In trabecular bone, GH mitigated the bone loss by increasing BFR/BS, whereas the 1OHD effect was by suppression of trabecular bone turnover in the HX rats. The combination of GH and 1OHD had no additive effect on increasing trabecular bone mass. In conclusion, GH activates new bone formation and increases bone turnover whereas 1OHD suppresses bone turnover. The combination intervention does not seem to provide any additive benefit.
authors.affiliation: Department of Pediatric Endocrinology, Winthrop University Hospital, Mineola, New York 11501, USA. drafshan@hotmail.com
authors.forename: Afshan A
authors.initials: AA
authors.lastname: Chaudhry
authors.forename: Mariano
authors.initials: M
authors.lastname: Castro-Magana
authors.forename: John F
authors.initials: JF
authors.lastname: Aloia
authors.forename: James K
authors.initials: JK
authors.lastname: Yeh
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001851:Bone Diseases, Metabolic / Q000188:drug therapy* / Q000503:physiopathology; D002113:Calcification, Physiologic / Q000187:drug effects; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D005260:Female; D005269:Femur / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000503:physiopathology; D019382:Human Growth Hormone / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D006887:Hydroxycholecalciferols / Q000008:administration & dosage / Q000494:pharmacology*; D007016:Hypophysectomy; D007279:Injections, Subcutaneous; D011859:Radiography; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000494:pharmacology; D013977:Tibia / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000503:physiopathology
chemical_list: D050071:Bone Density Conservation Agents; D006887:Hydroxycholecalciferols; D011994:Recombinant Proteins; D019382:Human Growth Hormone; C008088:alfacalcidol